To assess the predictive value of combining peripheral blood inflammatory markers, such as the aggregate index of systemic inflammation (AISI), with tumor markers, including Carcinoembryonic Antigen (CEA) and Cytokeratin 19 fragment antigen 21−1(CYFRA21−1), etc, for determining LUAD differentiation levels. This evidence concerns the gene CEACAM5 and neoplasm.